BBVA USA’s Teladoc Health TDOC Stock Holding History

BBVA USA’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-250	Closed	-$42K	–	1022
2021 Q2	$42K	Buy	+250	New	+$40.5K	﹤0.01%	699

Other funds holding TDOC

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCGM

General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

BBVA USA's TDOC Position: Q3 2021 in Review

BBVA USA sold out of Teladoc Health (TDOC) in Q3 2021, closing a stake of 250 shares — an estimated $42K sold.

BBVA USA first reported a position in TDOC in Q2 2021 and held it in 1 quarter. The position peaked at $42K in Q2 2021. 761 funds tracked by Wall St. Rank hold TDOC as of Q3 2021.

BBVA USA reported no remaining Teladoc Health position as of Q3 2021 after selling out during the quarter.
BBVA USA sold 250 Teladoc Health shares in Q3 2021, an estimated $42K.
BBVA USA first reported a position in Teladoc Health in Q2 2021 and held it in 1 quarter.
BBVA USA's Teladoc Health position peaked at $42K in Q2 2021.
761 funds tracked by Wall St. Rank held Teladoc Health as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.